Washington, DC
Foster City, CA
Miami, FL

30 Days, 30 Countries - daily #GreedyGilead advocacy starts June 1!
Gilead has priced several of its HIV and hepatitis C drugs out of reach for many people, refused to register some medications in developing countries, and consistently uses its patent monopolies to block attempts to introduce cheaper, generic versions of its medicines.
AHF is taking its grassroots campaign global to raise awareness about Gilead’s shameful practices and calling on the company to do the following:
- Stop evergreening patents on existing HIV/AIDS drugs like Truvada – this is exploitation, not innovation.
- Open the license for the generic production of the hepatitis C drug Harvoni to all low- and middle-income countries, without exception.
- For the duration of the COVID-19 pandemic, sell or license remdesivir for generic distribution at a nonprofit price.
- License technology to produce cryptococcal meningitis to generic manufacturers.
- Link executive compensation to the impact on positive public health outcomes and access to medicines in developing countries.

AIDS Healthcare Foundation 2023